Trump administration officials said the new payment incentives represent the biggest change in kidney care in decades.
CMS today finalized a new payment model it said would give patients greater access to home dialysis and kidney transplants from live donors, which officials said would improve outcomes and quality of life while saving Medicare $23 million over 5 years.
Trump administration officials said the model, which takes effect January 1, 2021, would be the biggest shift in decades in how Medicare manages kidney care. The stakes are huge: about 1% of all beneficiaries have kidney disease, but it accounts for 7% of all spending, including 20% of the dollars for those still in traditional Medicare, or $114 billion per year.
The End-Stage Renal Disease (ESRD) Treatment Choices (ETC) Model will be mandatory for 30% of kidney care providers—down from the 50% first proposed—and affect beneficiaries in all 50 states and the District of Columbia. A coalition of patient groups and dialysis providers and manufacturers warned that while CMS made some useful changes to its initial plan, some patients may still feel pushed into home care, and those who stick with dialysis centers may be at a disadvantage.
In recent years, an aging population and rising obesity rates have contributed to higher incidence of chronic kidney disease, which affects about 37 million people in the United States. More than 100,000 people reach ESRD in any given year, and 1 in 5 will die within 12 months. Promoting home-based dialysis has taken on new urgency during the coronavirus disease 2019 (COVID-19) pandemic, as patients who are treated at a dialysis center face a much higher risk of contracting the virus and dying from the disease.
“This new payment model helps address a broken set of incentives that have prevented far too many Americans from benefiting from enjoying the better lives that could come with more convenient dialysis options or the possibility of a transplant,” said HHS Secretary Alex Azar, who said he had personally seen the effect of misaligned incentives when his own father battled kidney disease before he died in April.
ESRD, Azar said, remains one of the glaring examples in medicine where the US health care system pays more for patients to be sick than to get them well, “and we don’t have very good outcomes to show for it.”
Azar’s father received a living donor transplant that added years to his life, but the HHS secretary said the donor faced “bureaucratic rules and restrictions.”
In a statement, CMS said the model “will test shifting Medicare payments from traditional fee-for-service payments to payments where providers are incentivized for encouraging receipt of home dialysis and kidney transplants.” Officials said the United States is far behind other developed countries in the share of ESRD patients receiving home dialysis, which was around 12% in 2016. Most patients who are on dialysis quickly qualify for Medicare regardless of age.
Elements of the new model include:
During a briefing with reporters, CMS Administrator Seema Verma said patients who are on home dialysis or who can get an early transplant fare better than other ESRD patients.
CMS said the new model allows flexibility for education about kidney care options to be provided by professionals other than a nephrologist. In its fact sheet, CMS said it would “monitor for potential coercion, steering, and inappropriate referrals to the targeted modalities by model participants,” and measure the effect of the model on hospitalization and mortality. The model spells out notification and attribution requirements.
However, the coalition Kidney Care Partners (KCP) said that while CMS had addressed some issues, concerns remain. “While the Model would expand the Kidney Disease Education benefit, we know that early education before patients enter the dialysis facilities is essential to helping patients understand and adopt home dialysis modalities,” the group said in a statement. KCP said waivers under the new model “do not include dialysis facilities and their multi-disciplinary care teams,” which are covered in legislation, The Chronic Kidney Disease Improvement in Research & Treatment Act.